SAMUEL NIX: Open Payments
NPI 1780075473 · TEXARKANA, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,485 in 78 payments from 15 companies in 2025. Trend: 2023 $1,591 · 2024 $1,075 · 2025 $1,485
Food & beverage: $1,485
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $301 |
| AstraZeneca Pharmaceuticals LP | 14 | $282 |
| Novo Nordisk Inc | 11 | $177 |
| EVOKE PHARMA, INC. | 5 | $157 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $139 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $138 |
| Amgen Inc. | 3 | $51 |
| Boston Scientific Corporation | 2 | $48 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $45 |
Products named: UBRELVY, GIMOTI, BREZTRI, CAPLYTA, AIRSUPRA, Kerendia, Rybelsus, VRAYLAR.
Industry payments across AR — which companies pay providers there.
